source
- Eli Lilly to pursue FDA approval for obesity drug in obstructive sleep apnea after positive Phase 3 trialEli Lilly announced that it will seek regulatory approval for its obesity medication as a treatment for obstructive sleep apnea, following a successful Phase 3 study. The trial showed positive res…
- Lilly's oral GLP-1 pill Foundayo reduces sleep apnea events in late-stage trialsIn two late-stage trials, Eli Lilly’s oral GLP‑1 pill Foundayo lowered the apnea‑hypopnea index by an average of 17.8 events per hour, compared with a 4.5‑event reduction for patients on placebo.…